7,8- Dihydroxyflavone prevents 3-NitropropionicAcid (3-NP)-induced Striatal Toxicity by Modulating the TrkB receptor and Microglial Activation Pathway
Objective: Hungtion’s disease (HD) is an autosomal governing neurodegenerative disorder caused by production of mutant hungtingtin(Htt) protein followed by death of the GABAergic neurons in…Successful altruistic living kidney donation in a patient with Huntington’s disease
Objective: To report a case of a Huntington’s Disease (HD) patient who underwent living kidney donation and examine the decision-making process and ethical considerations of…Tumor Pathology in Patients with Huntington’s Disease in a Specialized Center of Buenos Aires, Argentina (Preliminary Data)
Objective: To analyze the prevalence and type of neoplasms in patients with HD and to contrast it with the data of the general population in…Translating Preclinical Data to a Human Equivalent Dose for AMT-130 AAV Gene Therapy for Early Manifest Huntington’s Disease
Objective: To extrapolate the human equivalent dose (HED) for a Phase I/II clinical trial in adults to explore the safety, tolerability, and efficacy of striatally-administered…The History of Huntington Disease Description in Russia
Objective: The report provides detailed material on the history of the description of Huntington's disease (HD) in Russia. The first, unknown to a wide audience,…Sydenham’s Chorea: Realities and Challenges in Sub-Saharan Africa
Objective: The aim of this study was to describe the epidemiological, clinical, paraclinical and evolutive aspects of Sydenham's chorea. Background: Sydenham's chorea is a rare…Pallidotomy for Intractable Hemichorea in Sudden Hyperglicemic Pituitary Adenoma Patient
Objective: To prove that pallidotomy can be an alternative therapy for intractable chorea. Background: A 61 year old woman come with complaint sudden irregular movement…A randomized, double-blind, placebo-controlled Phase II Efficacy and Safety Study of the PDE10A inhibitor PF-02545920 in Huntington Disease (AMARYLLIS)
Objective: To assess efficacy on motor function, safety and tolerability of the phosphodiesterase-10A inhibitor PF-02545920 in Huntington disease (HD). Conclusion: PF-02545920 was generally safe and…Treating Huntington’s Disease using a holistic approach
Objective: Huntington’s disease (HD) is a fatal genetic disorder that causes the progressive breakdown of nerve cells in the brain. It deteriorates a person’s physical…Cognitive Reserve and Physical Activity Modulate Functional Brain Re-organisation in Premanifest Huntington’s Disease: Preliminary Evidence
Objective: In this study, for the first time we examined the relationship between cognitive reserve, sleep quality and current level of physical exercise and functional…
